Biosimilars to treat rheumatoid arthritis
In Switzerland, rheumatoid arthritis (RA) is often treated using the biologic infliximab. There are now various biosimilars available but they are not yet widely used. The HTA report examines the efficacy, safety and economic impact of biosimilars if they are used from the beginning of treatment and if patients are switched from the originator biologic infliximab to a biosimilar. It also analyses ethical, legal, social and organisational aspects of starting treatment with biosimilars or switching to a biosimilar.
Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
Switzerland - 3003 Bern
Health Technology Assessment Section
Schwarzenburgstrasse 157
Switzerland - 3003 Bern